Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/88320
DC Field | Value | Language |
---|---|---|
dc.contributor | Department of Applied Biology and Chemical Technology | - |
dc.creator | Xu, P | - |
dc.creator | Luo, H | - |
dc.creator | Kong, Y | - |
dc.creator | Lai, WF | - |
dc.creator | Cui, L | - |
dc.creator | Zhu, X | - |
dc.date.accessioned | 2020-10-29T01:02:24Z | - |
dc.date.available | 2020-10-29T01:02:24Z | - |
dc.identifier.uri | http://hdl.handle.net/10397/88320 | - |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Masson | en_US |
dc.rights | © 2020 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) | en_US |
dc.rights | The following publication Xu, P., Luo, H., Kong, Y., Lai, W. F., Cui, L., & Zhu, X. (2020). Cancer neoantigen: Boosting immunotherapy. Biomedicine & Pharmacotherapy, 131, 110640, is available at https://doi.org/10.1016/j.biopha.2020.110640 | en_US |
dc.subject | Immunotherapy | en_US |
dc.subject | Melanoma | en_US |
dc.subject | Neoantigen | en_US |
dc.subject | Personalized vaccine | en_US |
dc.subject | Tumor mutational burden | en_US |
dc.title | Cancer neoantigen : boosting immunotherapy | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.volume | 131 | - |
dc.identifier.doi | 10.1016/j.biopha.2020.110640 | - |
dcterms.abstract | Tumor neoantigen has a high degree of immunogenicity. As one of the emerging methods of tumor immunotherapy, the vaccine developed against it has served to clinical trials of various solid tumors, especially in the treatment of melanoma. Currently, a variety of immunotherapy methods have been applied to the treatment of the tumor. However, other therapeutic methods have the disadvantages of low specificity and prominent side effects. Treatments require tumor antigen with higher immunogenicity as the target of immune attack. This review will recommend the identification of neoantigen, the influencing factors of neoantigen, and the application of personalized vaccines for neoantigen in metastatic tumors such as malignant melanoma. | - |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | Biomedicine and pharmacotherapy, 2020, v. 131, 110640 | - |
dcterms.isPartOf | Biomedicine and pharmacotherapy | - |
dcterms.issued | 2020 | - |
dc.identifier.scopus | 2-s2.0-85089530920 | - |
dc.identifier.eissn | 0753-3322 | - |
dc.identifier.artn | 110640 | - |
dc.description.validate | 202010 bcma | - |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | OA_Scopus/WOS | en_US |
dc.description.pubStatus | Published | en_US |
dc.description.oaCategory | CC | en_US |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Xu_Cancer_neoantigen_Boosting.pdf | 1.77 MB | Adobe PDF | View/Open |
Page views
75
Last Week
0
0
Last month
Citations as of Oct 13, 2024
Downloads
52
Citations as of Oct 13, 2024
SCOPUSTM
Citations
45
Citations as of Oct 17, 2024
WEB OF SCIENCETM
Citations
41
Citations as of Oct 17, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.